← Leaderboards
Scott Carter
Massachusetts General Hospital
$2,798,679
Attributed
$6,650,717
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,650,717 · 3
By mechanism
R01$6,229,809 · 2
R21$420,908 · 1
Top collaborators
- Priscilla Kaliopi Brastianos11 shared
- Elizabeth Gerstner4 shared
- Toni Choueiri2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- E. Antonio Chiocca$34,514,665
- Anand Viswanathan$12,542,460
- Priscilla Kaliopi Brastianos$4,062,816
- Elyse R Park$12,238,672
- Elizabeth Gerstner$2,756,329
Others in their field
Other Emerging Leaders on “Histology”
- John Freymann · Leidos Biomedical Research, Inc.$14,011,208
- Thomas Steinbach · Experimental Pathology Laboratories$11,153,684
- Crystal Mackall · Children'S Hosp Of Philadelphia$10,785,733
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,153,043
- Shadi Dayeh · University Of California, San Diego$9,482,559
- Gabriel Nestor Sanchez · Enspectra Health, Inc.$7,941,485
Research focus
HistologyMutationInsightPathway InteractionsClinical TrialsTargeted TreatmentData SetMetastatic Malignant Neoplasm To BrainNovel TherapeuticsBurden Of IllnessCollectionImmunotherapyChemotherapyTissue SampleMalignant NeoplasmsMetastatic Neoplasm To The Central Nervous SystemClonal EvolutionMalignant Neoplasm Of LungGenesGenomicsBrainCohortDesignDna Sequence Alteration
Grant awards (11)
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2023 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2022 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$666,767
R01 · FY2022 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2021 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$694,319
R01 · FY2021 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases$711,319
R01 · FY2020 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$695,450
R01 · FY2020 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$674,587
R01 · FY2019 · CA
Identification of genomic drivers of brain metastases in renal cell carcinoma$181,867
R21 · FY2019 · CA
Identification of genomic drivers of brain metastases in lung adenocarcinoma$729,700
R01 · FY2018 · CA
Identification of genomic drivers of brain metastases in renal cell carcinoma$239,041
R21 · FY2018 · CA